- Details
- Description
-
Packaging Size120t/Bottle
-
Strength80mg
-
CompositonSonrotoclax
-
TreatmentMantle cell lymphoma
-
FormTablet
-
BrandBEQALZ™I (百悦达®)
-
Quantity Unit80mg*120t/Box
-
ManufacturerBeOne Medicines Ltd.,China
About Sonrotoclax
Sonrotoclax is a potent and selective BCL2 inhibitor that can overcome resistance associated with BCL2 mutations, such as the G101V variant, which limits the effectiveness of first-generation inhibitors like venetoclax.
The FDA has granted accelerated approval to sonrotoclax (Beqalzi) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least 2 lines of systemic therapy, including a BTK inhibitor.
Doseage
Sonrotoclax dosing is recommended to begin with a 4-week ramp-up phase to reduce the risk of TLS, followed by 320 mg once per day until disease progression or unacceptable toxicity.
Dosage specifications
- 1mg*11t/Box
- 5mg*11t/Box
- 20mg*11t/Box
- 80mg*120t/Box